Three gene therapy pioneers behind the first U.S.-approved gene therapy received the Breakthrough Prize in Life Sciences, recognizing foundational work that helped move gene transfer from concept to approved medicines. The award highlights milestone progress in clinical translation, from vector biology to clinical trial execution. The honorees’ contributions underscore how early gene therapy platforms matured into regulatory-grade evidence packages. The prize also signals continued momentum as gene therapy developers expand indications and delivery formats. For industry participants, the recognition comes as the sector’s pipeline increasingly depends on durable benefit, manufacturability, and delivery improvements across diverse therapeutic targets.